These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36670545)

  • 1. Discovery of Norbornene as a Novel Hydrophobic Tag Applied in Protein Degradation.
    Xie S; Zhan F; Zhu J; Sun Y; Zhu H; Liu J; Chen J; Zhu Z; Yang DH; Chen ZS; Yao H; Xu J; Xu S
    Angew Chem Int Ed Engl; 2023 Mar; 62(13):e202217246. PubMed ID: 36670545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
    Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
    Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
    Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
    Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras.
    Wang Y; Han L; Liu F; Yang F; Jiang X; Sun H; Feng F; Xue J; Liu W
    Colloids Surf B Biointerfaces; 2020 Apr; 188():110795. PubMed ID: 31991291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
    Barghout SH
    Anticancer Agents Med Chem; 2021; 21(2):214-230. PubMed ID: 32275492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrophobic tag-based protein degradation: Development, opportunity and challenge.
    He Q; Zhao X; Wu D; Jia S; Liu C; Cheng Z; Huang F; Chen Y; Lu T; Lu S
    Eur J Med Chem; 2023 Nov; 260():115741. PubMed ID: 37607438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-Molecule Hydrophobic Tagging: A Promising Strategy of Druglike Technology for Targeted Protein Degradation.
    Xie S; Zhu J; Li J; Zhan F; Yao H; Xu J; Xu S
    J Med Chem; 2023 Aug; 66(16):10917-10933. PubMed ID: 37535706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
    Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
    J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib.
    Ren C; Sun N; Kong Y; Qu X; Liu H; Zhong H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2021 May; 217():113335. PubMed ID: 33751979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
    Chen H; Chen F; Liu N; Wang X; Gou S
    Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrophobic tagging of small molecules: an overview of the literature and future outlook.
    Zhou Y; Zhou F; Xu S; Shi D; Ding D; Wang S; Poongavanam V; Tang K; Liu X; Zhan P
    Expert Opin Drug Discov; 2024 Jul; 19(7):799-813. PubMed ID: 38825802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
    Wang S; Luo D; Pu C; Ma X; Zhang H; Feng Z; Deng R; Yu S; Liu Y; Huang Q; Li R
    Eur J Med Chem; 2023 Feb; 248():115082. PubMed ID: 36628851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a PROTAC targeting ALK with in vivo activity.
    Yan G; Zhong X; Yue L; Pu C; Shan H; Lan S; Zhou M; Hou X; Yang J; Li R
    Eur J Med Chem; 2021 Feb; 212():113150. PubMed ID: 33453602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Brigatinib degrader (SIAIS117) as a potential treatment for ALK positive cancer resistance.
    Sun N; Ren C; Kong Y; Zhong H; Chen J; Li Y; Zhang J; Zhou Y; Qiu X; Lin H; Song X; Yang X; Jiang B
    Eur J Med Chem; 2020 May; 193():112190. PubMed ID: 32179332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced protein degradation by intracellular delivery of pre-fused PROTACs using lipid-like nanoparticles.
    Chen J; Qiu M; Ma F; Yang L; Glass Z; Xu Q
    J Control Release; 2021 Feb; 330():1244-1249. PubMed ID: 33234362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
    Go A; Jang JW; Lee W; Ha JD; Kim HJ; Nam HJ
    Eur J Med Chem; 2020 Oct; 204():112635. PubMed ID: 32726747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual degradation mechanism of GPX4 degrader in induction of ferroptosis exerting anti-resistant tumor effect.
    Wang C; Zheng C; Wang H; Shui S; Jin H; Liu G; Xu F; Liu Z; Zhang L; Sun D; Xu P
    Eur J Med Chem; 2023 Feb; 247():115072. PubMed ID: 36603510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrophobic Tagging-Mediated Degradation of Transcription Coactivator SRC-1.
    Choi SR; Wang HM; Shin MH; Lim HS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical Studies of PROTACs in Hematological Malignancies.
    Fuchs O; Bokorova R
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):7-22. PubMed ID: 33687890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.